Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Engert, A; Haverkamp, H; Kobe, C; Markova, J; Renner, C; Ho, A; Zijlstra, J; Král, Z; Fuchs, M; Hallek, M; Kanz, L; Döhner, H; Dörken, B; Engel, N; Topp, M; Klutmann, S; Amthauer, H; Bockisch, A; Kluge, R; Kratochwil, C; Schober, O; Greil, R; Andreesen, R; Kneba, M; Pfreundschuh, M; Stein, H; Eich, H T; Müller, R P; Dietlein, M; Borchmann, P; Diehl, V (2012). Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379(9828):1791-1799.

Pfreundschuh, M; Kuhnt, E; Trümper, L; Osterborg, A; Trneny, M; Shepherd, L; Gill, D S; Walewski, J; Pettengell, R; Jaeger, U; Zinzani, P L; Shpilberg, O; Kvaloy, S; de Nully Brown, P; Stahel, R; Milpied, N; López-Guillermo, A; Poeschel, V; Grass, S; Loeffler, M; Murawski, N (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, 12(11):1013-1022.

Lugthart, S; Gröschel, S; Beverloo, H B; Kayser, S; Valk, P J; van Zelderen-Bhola, S L; Ossenkoppele, G J; Vellenga, E; van den Berg-de Ruiter, E; Schanz, U; Verhoef, G; Vandenberghe, P; Ferrant, A; Köhne, C H; Pfreundschuh, M; Horst, H A; Schlegelberger, H; Jotterand, M; Krauter, J; Pabst, T; Theobald, M; Schlenk, R F; Delwel, R; Döhner, K; Löwenberg, B; Döhner, H (2010). Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Journal of Clinical Oncology, 28(24):3890-3899.

Held, G; Neumann, F; Sturm, C; Kaestner, L; Dauth, N; de Bruijn, D R; Renner, C; Lipp, P; Pfreundschuh, M (2008). Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. International Journal of Cancer, 123(8):1841-1847.

Kaiser, U; Uebelacker, I; Abel, U; Birkmann, J; Trümper, L; Schmalenberg, H; Karakas, T; Metzner, B; Hossfeld, D K; Bischoff, H G; Franke, A; Reiser, M; Müller, P; Mantovani, L; Grundeis, M; Rothmann, F; von Seydewitz, C U; Mesters, R M; Steinhauer, E U; Krahl, D; Schumacher, K; Kneba, M; Baudis, M; Schmitz, N; Pfab, R; Köppler, H; Parwaresch, R; Pfreundschuh, M; Havemann, K (2002). Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. Journal of Clinical Oncology, 20(22):4413-4419.

Bentz, M; Döhner, H; Werner, C A; Huck, K; Baudis, M; Joos, S; Schlegelberger, B; Trümper, L H; Feller, A C; Pfreundschuh, M (1995). Identification of genetic imbalances in malignant lymphoma using comparative genomic hybridization. Stem Cells, 13(3):83-87.

This list was generated on Sat Dec 16 14:41:56 2017 CET.